Krouzon Pharmaceuticals

Executive Summary

Krouzon Pharmaceuticals is a preclinical-stage biotechnology company founded in 2019 and headquartered in San Diego, California. The company is dedicated to developing first-in-class pharmacological therapies for FGFR2-related syndromic craniosynostosis, a group of severe pediatric rare diseases characterized by premature fusion of cranial sutures. Founded by Dr. Jacob Eswarakumar, a former Yale professor and a pioneer in FGFR signaling research, Krouzon leverages deep expertise in fibroblast growth factor receptor biology to address critical unmet medical needs. The company's approach aims to provide a non-surgical alternative for children suffering from these debilitating conditions, which currently lack approved pharmacological treatments. Krouzon is privately held and operates at the preclinical stage, focusing on advancing its lead candidates through IND-enabling studies and toward initial clinical trials.

Upcoming Catalysts (preview)

• Q1 2027Completion of IND-Enabling Toxicology Studies60% success
• Q2 2026Orphan Drug Designation from FDA75% success
• Q4 2026Publication of Preclinical In Vivo Efficacy Data70% success